Printed From BioPortfolio.com
Novo Nordisk A/S: Status regarding Novo Nordisk's holding of its own shares (31 December 2017)
06:15 EST 2 Jan 2018 | GlobalNewsWire (2014)
Bagsværd, Denmark, 2 January 2018 - In continuation of the company's announcements dated 9 August 2017 and 1 November 2017 concerning planned share repurchase programmes, and pursuant to Section 204.25 of the New York Stock Exchange Listed Company Manual, this is to report that Novo Nordisk A/S (NYSE: NVO) and its wholly-owned affiliates on 31 December 2017 owned 55,542,054 of its own B shares of DKK 0.20, corresponding to a total nominal value of DKK 11,108,411 or 2.2% of the total share capital.
In the fourth quarter of 2017 a total of 13,925,270 B shares were repurchased, and 4,329 B shares were disposed to employees in connection with employee incentive programmes.
Further information
| Media: | ||
| Anne Margrethe Hauge | +45 4442 3450 | amhg@novonordisk.com |
| Ken Inchausti (US) | +1 609 786 8316 | kiau@novonordisk.com |
| Investors: | ||
| Peter Hugreffe Ankersen | +45 3075 9085 | phak@novonordisk.com |
| Hanna Ögren | +45 3079 8519 | haoe@novonordisk.com |
| Anders Mikkelsen | +45 3079 4461 | armk@novonordisk.com |
| Christina Kjær | +45 3079 3009 | cnje@novonordisk.com |
| Kasper Veje (US) | +1 609 235 8567 | kpvj@novonordisk.com |
Company announcement no. 1/2018
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Novo Nordisk A/S via Globenewswire
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Novo Nordisk A/S via Globenewswire
